losartan and Chronic Lung Injury

losartan has been researched along with Chronic Lung Injury in 4 studies

Losartan: An antagonist of ANGIOTENSIN TYPE 1 RECEPTOR with antihypertensive activity due to the reduced pressor effect of ANGIOTENSIN II.
losartan : A biphenylyltetrazole where a 1,1'-biphenyl group is attached at the 5-position and has an additional trisubstituted imidazol-1-ylmethyl group at the 4'-position

Research

Studies (4)

Authors

Clinical Trials (1)

Trial Overview

Trial Outcomes

28-Day Mortality

Outcome reported as the number of participants who have expired at 28 days post enrollment. (NCT04312009)
Timeframe: 28 days

90-Day Mortality

Outcome reported as the number of participants who have expired at 90 days post enrollment. (NCT04312009)
Timeframe: 90 days

Change in Viral Load by Nasopharyngeal Swab Day 15

Nasopharyngeal swabs will be collected at baseline and day 15. Viral load is measured as number of viral genetic copies per mL. (NCT04312009)
Timeframe: 15 days

Daily Hypotensive Episodes

Outcome reported as the mean number of daily hypotensive episodes (MAP < 65 mmHg) prompting intervention (indicated by a fluid bolus >=500 mL) per participant in each arm. (NCT04312009)
Timeframe: 10 days

Difference in Estimated (PEEP Adjusted) P/F Ratio at 7 Days

Outcome calculated from the partial pressure of oxygen or peripheral saturation of oxygen by pulse oximetry divided by the fraction of inspired oxygen (PaO2 or SaO2 : FiO2 ratio). PaO2 is preferentially used if available. A correction is applied for endotracheal intubation and/or positive end-expiratory pressure. Patients discharged prior to day 7 will have a home pulse oximeter send home for measurement of the day 7 value, and will be adjusted for home O2 use, if applicable. Patients who died will be applied a penalty with a P/F ratio of 0. (NCT04312009)
Timeframe: 7 days

Disease Severity Rating

Outcome reported as the number of participants in each arm who fall into each of 7 categories. Lower scores indicate greater condition severity. The ordinal scale is an assessment of the clinical status at the first assessment of a given study day. The scale is as follows: 1) Death; 2) Hospitalized, on invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO); 3) Hospitalized, on non-invasive ventilation or high flow oxygen devices; 4) Hospitalized, requiring supplemental oxygen; 5) Hospitalized, not requiring supplemental oxygen; 6) Not hospitalized, limitation on activities; 7) Not hospitalized, no limitations on activities. (NCT04312009)
Timeframe: 28 days

ICU Admission

Outcome reported as the number of participants in each arm who require admission to the Intensive Care Unit (ICU). (NCT04312009)
Timeframe: 10 days

Length of Hospital Stay

Outcome reported as the mean length of in-patient hospital stay (in days) for participants in each arm. (NCT04312009)
Timeframe: 90 days

Number of Therapeutic Oxygen-Free Days

Outcome reported as the mean number of days participants in each arm did not require therapeutic oxygen usage during an in-patient hospital admission. (NCT04312009)
Timeframe: 28 days

Number of Vasopressor-Free Days

Outcome reported as the mean number of days participants in each arm did not require vasopressor usage during an in-patient hospital admission. (NCT04312009)
Timeframe: 10 days

Number of Ventilator-Free Days

Outcome reported as the mean number of days participants in each arm did not require mechanical ventilation during an in-patient hospital admission. (NCT04312009)
Timeframe: 28 days

Oxygen Saturation / Fractional Inhaled Oxygen (S/F)

Oxygen saturation (percent) is measured by pulse oximeter. Fraction of inspired oxygen (FiO2) (unitless) is the volumetric fraction of oxygen to other gases in respiratory support. The S/F ratio is unitless. (NCT04312009)
Timeframe: 7 days

Proportion of Participants Experiencing Acute Kidney Injury

"Outcome reported as the number of participants in each arm who experience acute kidney injury as defined by the Kidney Disease Improving Global Outcomes (KDIGO) guidelines:~Increase in serum creatinine by 0.3mg/dL or more within 48 hours OR Increase in serum creatinine to 1.5 times baseline or more within the last 7 days OR Urine output less than 0.5 mL/kg/h for 6 hours." (NCT04312009)
Timeframe: 10 days

Proportion of Participants Requiring Vasopressors for Hypotension

Outcome reported as the number of participants in each arm requiring the use of vasopressors for hypotension. (NCT04312009)
Timeframe: 10 days

Trials

1 trial available for losartan and Chronic Lung Injury

Other Studies

3 other studies available for losartan and Chronic Lung Injury